| Working Out M0 Bipolar Androgen Therapy (NCT06594926) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2024-08-14 |
| Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (NCT04918810) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2022-07-29 |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (NCT05150236) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2022-04-29 |
| Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (NCT04419402) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2020-08-17 |
| ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (NCT03685448) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2019-04-11 |
| A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (NCT03392428) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2018-01-29 |
| Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (NCT03280667) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2017-12-12 |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (NCT03177239) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2017-10-19 |
| Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer (NCT02662062) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2017-07-11 |